🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07570680
Recruiting Observational

Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)

NCT07570680 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital of Nanchang University
Phase
Observational
Started
2022-09-01
Last updated
2026-05-06

Condition(s) studied

Hemorrhage Stroke

Investigational drug(s) / intervention(s)

Large language model

Large language model: Automatical diagnosis, treatment decision-making, and risk prediction after spontaneous intracerebral hemorrhage via a trained deep learning larger language model.

Study summary

Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is still limited to the traditional Tada formula, and there are subjective differences in diagnosis among different doctors, making it difficult to achieve homogenization in clinical decision-making. Hemorrhagic stroke is a common and frequently occurring disease in Jiangxi Province. Therefore, establishing a new diagnosis and treatment system focused on hemorrhagic stroke can not only fill the research gap in this field in China, improve the accuracy and homogeneity of hemorrhagic stroke diagnosis and treatment, but also promote related research progress to reduce the mortality and disability rates of this disease and improve the clinical prognosis of patients.

Eligibility

Sex
ALL
Min age
8 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age \>= 8 years old; 2. Patients diagnosed with spontaneous hemorrhagic stroke based on medical history and auxiliary examinations; 3. Received non-contrast computed tomography (NCCT) in the outpatient or emergency department; 4. Treated in accordance with standard clinical guidelines during hospitalization; 5. Have complete clinical data. Exclusion Criteria: 1. Had undergone surgical treatment in another hospital before admission; 2. Was in a state of shock upon admission; 3. Had severe heart, liver, or kidney dysfunction or other life-threatening systemic diseases; 4. Died during hospitalization; 5. Had an expected lifespan of less than six months or was unable to complete the study follow-up for other reasons.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital of Nanchang University Nanchang China Recruiting

More Second Affiliated Hospital of Nanchang University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07570680 on ClinicalTrials.gov ↗ ← All trials in China